2023
41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials
Strober B, Kircik L, Green L, Lockshin B, Brown P, Tallman A. 41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials. Journal Of The American Academy Of Dermatology 2023, 89: ab92. DOI: 10.1016/j.jaad.2023.07.371.Peer-Reviewed Original ResearchTapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Strober B, Zeichner J, Desai S, Cameron M, Cather J, Bruno M, Rubenstein D, Tallman A, Brown P. Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial. SKIN The Journal Of Cutaneous Medicine 2023, 7: s125. DOI: 10.25251/skin.7.supp.125.Peer-Reviewed Original Research
2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Kircik L, Tyring S, Piscitelli S, Brown P, Rubenstein D, Tallman A, Lebwohl M. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. Journal Of The American Academy Of Dermatology 2022, 87: 800-806. PMID: 35772599, DOI: 10.1016/j.jaad.2022.06.1171.Peer-Reviewed Original ResearchConceptsOpen-label treatmentRemittive effectsPlaque psoriasisUpper respiratory tract infectionPhysician Global Assessment scoreComplete disease clearanceOne-year safetyFrequent adverse eventsSevere plaque psoriasisNew safety signalsPhase 3 trialRespiratory tract infectionsDurability of responseForms of psoriasisGlobal assessment scoreLong-term safetyEligible patientsTapinarof creamDisease clearanceAdverse eventsTract infectionsMean durationSafety signalsContact dermatitisCream 1Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Kircik L, Brown P, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2022, 6: s5. DOI: 10.25251/skin.6.supp.5.Peer-Reviewed Original Research
2021
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Brown P, Kircik L, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2021, 5: s35. DOI: 10.25251/skin.5.supp.35.Peer-Reviewed Original Research25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials
Bissonnette R, Strober B, Lebwohl M, Bagel J, Del Rosso J, Merola J, Bhatia N, Yamauchi P, Brown P, Rubenstein D, Tallman A. 25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials. Journal Of The American Academy Of Dermatology 2021, 85: ab71. DOI: 10.1016/j.jaad.2021.06.310.Peer-Reviewed Original Research
2020
Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials
Lebwohl M, Stein Gold L, Strober B, Armstrong A, Hong H, Kircik L, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonnette R. Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. SKIN The Journal Of Cutaneous Medicine 2020, 4: s75. DOI: 10.25251/skin.4.supp.75.Peer-Reviewed Original Research
2010
Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial
Bangert C, Strober B, Cork M, Ortonne J, Luger T, Bieber T, Ferguson A, Ecker R, Kopp T, Weise-Riccardi S, Guettner A, Stingl G. Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology 2010, 222: 36-48. PMID: 21150167, DOI: 10.1159/000321711.Peer-Reviewed Original ResearchConceptsPimecrolimus cream 1End of studyCream 1Vehicle creamTopical pimecrolimusAD lesionsAtopic dermatitisDouble-blind treatmentDermal dendritic cellsProportion of patientsAtopic dermatitis lesionsNumber of leukocytesAD remissionEczema AreaPlacebo creamSubclinical inflammationTopical corticosteroidsControlled TrialsDendritic cellsInflammatory infiltrateLangerhans cellsNonsignificant reductionSkin biopsiesT cellsOutcome measures